DUMAC Inc’s Ocular Therapeutix OCUL Stock Holding History

DUMAC Inc’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-57,359	Closed	-$941K	–	35
2021 Q1	$941K	Buy	57,359 +19,792	+53%	+$381K	1.3%	11
2020 Q4	$778K	Buy	+37,567	New	+$558K	0.61%	17

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

DUMAC Inc's OCUL Position: Q2 2021 in Review

DUMAC Inc sold out of Ocular Therapeutix (OCUL) in Q2 2021, closing a stake of 57,359 shares — an estimated $941K sold.

DUMAC Inc first reported a position in OCUL in Q4 2020 and held it in 2 quarters. The position peaked at $941K in Q1 2021. 149 funds tracked by Wall St. Rank hold OCUL as of Q2 2021.

DUMAC Inc reported no remaining Ocular Therapeutix position as of Q2 2021 after selling out during the quarter.
DUMAC Inc sold 57,359 Ocular Therapeutix shares in Q2 2021, an estimated $941K.
DUMAC Inc first reported a position in Ocular Therapeutix in Q4 2020 and held it in 2 quarters.
DUMAC Inc's Ocular Therapeutix position peaked at $941K in Q1 2021.
149 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2021.

Based on DUMAC Inc's 13F filing for Q2 2021, filed 16 Aug 2021.